Skip to main content
Fig. 3 | Cancer Cell International

Fig. 3

From: Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma

Fig. 3

The histone deacetylase (HDAC) inhibitor trichostatin (TSA) downregulated BET expression and suppressed the growth of osimertinib resistant cells and xenograft tumors. a–d Osimertinib sensitive parental (H1975-P) and osimertinib resistant (H1975-OR) cells were either treated with TSA (a) or vorinostat (b) for 24 h and subjected to western blot analysis or treated with TSA (c) or vorinostat (d) for 3 days and subjected to sulforhodamine B (SRB) assays as indicated. E, The mRNA levels of BETs under TSA (1 μmol/L) treatment for 6 h. F, Cells were transfected with c-Myc or control siRNAs as indicated, and subjected to SRB assays and Western blotting. Columns, mean; Points, mean; bars, SD; *, P < 0.05. g–i A schematic diagram of experiment design, the tumor size (g), tumor weight (h), and body weight (i) are indicated. TSA (0.5 mg/kg/d) or vehicle was administered for 21 days. G columns, mean. H points, individual tumor weight; horizontal line, mean tumor weight. I points, mean. Bars, SD; *, P < 0.05

Back to article page